Arterial stiffness in chronic kidney disease: An update

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 2, 2014, Pages 169-173

  Taal, Maarten W ^a  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

Author keywords

Arterial stiffness; Chronic kidney disease; Pulse wave velocity

Indexed keywords

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; VASCULAR STIFFNESS;

EID: 84894054166     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000441153.40072.e0     Document Type: Review

References (35)

1. Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 2010; 96:817-823.
2. Taal MW, Sigrist MK, Fakis A, et al. Markers of arterial stiffness are risk factors for progression to end-stage renal disease among patients with chronic kidney disease stages 4 and 5 Nephron Clin Pract 2007;107:c177-c181.
3. Ford ML, Tomlinson LA, Chapman TP, et al. Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4 Hypertension 2010; 55:1110-1115.
4. Chue CD, Edwards NC, Davis L J, et al. Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. Nephrol Dial Transplant 2011; 26:2576-2582.
5. Tomlinson L A. Methods for assessing arterial stiffness: technical considerations. Curr Opin Nephrol Hypertens 2012; 21:655-660.
6. Hickson SS, Butlin M, Broad J, et al. Validity and repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device. Hypertens Res 2009; 32:1079-1085.
7. Baulmann J, Schillings U, Rickert S, et al. A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezoelectronic methods. J Hypertens 2008; 26:523-528.
8. Karras A, Haymann JP, Bozec E, et al. Large artery stiffening and remodeling are independently associated with all-cause mortality and cardiovascular events in chronic kidney disease. Hypertension 2012; 60:1451-1457.
9. Claes KJ, Heye S, Bammens B, et al. Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients. Transpl Int 2013; 26:973-981.
10. Peralta CA, Jacobs DR Jr, Katz R, et al. Association of pulse pressure, arterial elasticity, and endothelial function with kidney function decline among adults with estimated GFR>60 mL/min/1.73 m(2): the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2012; 59:41-49.
11. Madero M, Peralta C, Katz R, et al. Association of arterial rigidity with incident kidney disease and kidney function decline: the Health ABC study. Clin J Am Soc Nephrol 2013; 8:424-433.
12. Scialla JJ, Lau WL, Reilly MP, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013; 83:1159-1168.
13. Desjardins L, Liabeuf S, Renard C, et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012; 23:2017-2025.
14. Houston J, Smith K, Isakova T, et al. Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. J Ren Nutr 2013; 23:12-20.
15. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393-4408.
16. Six I, Maizel J, Barreto FC, et al. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res 2012; 96:130-139.
17. Ix JH, De Boer IH, Peralta CA, et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4:609-615.
18. Kitagawa M, Sugiyama H, Morinaga H, et al. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One 2013; 8:e56695.
19. Pateinakis P, Papagianni A, Douma S, et al. Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. BMC Nephrol 2013; 14:122.
20. Meerwaldt R, Hartog JW, Graaff R, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:3687-3693.
21. Arsov S, Trajceska L, van Oeveren W, et al. Increase in skin autofluorescence and release of heart-type fatty acid binding protein in plasma predicts mortality of hemodialysis patients. Artif Organs 2013; 37:E114-E122.
22. Ueno H, Koyama H, Tanaka S, et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 2008; 57:1452-1457.
23. McIntyre NJ, Fluck RJ, McIntyre CW, et al. Determinants of arterial stiffness in chronic kidney disease stage. PLoS One 2013; 8:e55444.
24. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage. Clin J Am Soc Nephrol 2011; 6:2356-2363.
25. Utescu MS, Couture V, Mac-Way F, et al. Determinants of progression of aortic stiffness in hemodialysis patients: a prospective longitudinal study. Hypertension 2013; 62:154-160.
26. Strozecki P, Kurowski R, Flisinski M, et al. Advanced glycation end products and arterial stiffness in diabetic and nondiabetic patients with chronic kidney disease. Pol Arch Med Wewn 2013; 123:609-616.
27. Wall NA, Chue CD, Edwards NC, et al. Cytomegalovirus seropositivity is associated with increased arterial stiffness in patients with chronic kidney disease. PLoS One 2013; 8:e55686.
28. Olden M, Teumer A, Bochud M, et al. Overlap between common genetic polymorphisms underpinning kidney traits and cardiovascular disease phenotypes: the CKDGen consortium. Am J Kidney Dis 2013; 61:889-898.
29. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103:987-992.
30. Mitchell GF, Dunlap ME, Warnica W, et al. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 2007; 49:1271-1277.
31. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009; 54:505-512.
32. Boesby L, Elung-Jensen T, Strandgaard S, Kamper AL. Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4-a randomized controlled study. PLoS One 2013; 8:e64549.
33. Maizel J, Six I, Dupont S, et al. Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure. Kidney Int 2013; 84:491-500.
34. Chue CD, Townend JN,Moody WE, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 2013; 24:842-852.
35. Seifert ME, de las Fuentes L, Rothstein M, et al. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol 2013; 38:158-167.